Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.46 |
| ▸ | AVPR2 | P30518 | 9/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.40 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5234007 | 0.89 | SLC22A12 (0.44) | SLC22A12AVPR2AVPR1A | |
| SCHEMBL5229164 | 0.83 | AVPR2 (0.43) | SLC22A12AVPR2AVPR1AOXTRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5235888 | 0.80 | AVPR2 (0.47) | AVPR2 | |
| SCHEMBL1346034 | 0.80 | SLC22A12 (0.61) | SLC22A12AVPR2AVPR1AOXTRPDE4A | |
| SCHEMBL5235559 | 0.78 | AVPR1A (0.57) | SLC22A12AVPR2AVPR1AOXTRPDE4A | |
| SCHEMBL5230491 | 0.78 | AVPR2 (0.57) | SLC22A12AVPR2AVPR1APDE4APDE4B | |
| SCHEMBL6202811 | 0.73 | BRD4 (0.60) | SLC22A12TSHRSMN1; SMN2 | |
| SCHEMBL4837451 | 0.72 | AVPR1A (0.54) | SLC22A12AVPR2AVPR1AOXTRSMN1; SMN2 | |
| SCHEMBL2938321 | 0.72 | AVPR2 (0.47) | AVPR2AVPR1APDE4APDE4BPDE4C | |
| SCHEMBL5230053 | 0.72 | AVPR2 (0.74) | AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1294698-B1 | FUSED AZEPINE DERIVATIVES AND THEIR USE AS ANTIDIURETIC AGENTS | FERRING BV (NL) | 2007-08-01 | — | — | EP | disclosed |
| US-7176195-B2 | Fused azepine derivatives and their use as antidiuretic agents | FERRING BV (NL) | 2007-02-13 | — | — | US | disclosed |
| US-20040038962-A1 | Fused azepine derivatives and their use as antidiuretic agents | VANTIA LIMITED (GB) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038962-A1 | Fused azepine derivatives and their use as antidiuretic agents | AVPR2, AVPR1A, AVPR1B | SLC22A12 1223/4885AVPR2 1/4885AVPR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.